FBC
ABBV icon

Fairfield, Bush & Co’s AbbVie ABBV Stock Holding History

Fairfield, Bush & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Sell
6,755
-141
-2% -$31.3K 0.82% 37
2025
Q4 		$1.58M Buy
6,896
+729
+12% +$166K 0.83% 35
2025
Q3 		$1.43M Buy
6,167
+152
+3% +$31K 0.73% 37
2025
Q2 		$1.12M Sell
6,015
-16
-0.3% -$2.97K 0.63% 45
2025
Q1 		$1.26M Sell
6,031
-218
-3% -$42.4K 0.8% 37
2024
Q4 		$1.11M Buy
6,249
+2,739
+78% +$504K 0.65% 44
2024
Q3 		$693K Buy
3,510
+335
+11% +$62.5K 0.41% 63
2024
Q2 		$545K Sell
3,175
-943
-23% -$156K 0.33% 61
2024
Q1 		$750K Sell
4,118
-773
-16% -$133K 0.44% 57
2023
Q4 		$758K Sell
4,891
-388
-7% -$56.6K 0.44% 55
2023
Q3 		$787K Sell
5,279
-198
-4% -$29.1K 0.51% 50
2023
Q2 		$738K Sell
5,477
-222
-4% -$32.6K 0.2% 89
2023
Q1 		$908K Sell
5,699
-923
-14% -$141K 0.32% 71
2022
Q4 		$1.07M Sell
6,622
-48
-0.7% -$7.36K 0.71% 39
2022
Q3 		$895K Buy
6,670
+834
+14% +$120K 0.63% 42
2022
Q2 		$894K Sell
5,836
-2,868
-33% -$438K 0.53% 46
2022
Q1 		$1.41M Sell
8,704
-667
-7% -$96.9K 0.71% 36
2021
Q4 		$1.27M Buy
9,371
+972
+12% +$115K 0.61% 42
2021
Q3 		$906K Buy
8,399
+2,435
+41% +$278K 0.29% 75
2021
Q2 		$671K Buy
5,964
+400
+7% +$45K 0.18% 96
2021
Q1 		$602K Sell
5,564
-501
-8% -$53.6K 0.17% 106
2020
Q4 		$650K Buy
6,065
+2,125
+54% +$204K 0.19% 97
2020
Q3 		$345K Buy
+3,940
New +$371K 0.11% 114
2018
Q2 		– Sell
-1,540
Closed -$146K – 158
2018
Q1 		$146K Buy
+1,540
New +$169K 0.04% 157

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fairfield, Bush & Co's ABBV Position: Q1 2026 in Review

Fairfield, Bush & Co reduced its AbbVie (ABBV) stake by 2% in Q1 2026, selling an estimated $31.3K and leaving 6,755 shares worth $1.47M. The position accounts for 0.82% of the portfolio, ranked #37.

Fairfield, Bush & Co first reported a position in ABBV in Q1 2018 and has held it in 24 quarters since. The position peaked at $1.58M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Fairfield, Bush & Co held 6,755 shares of AbbVie worth $1.47M as of Q1 2026.
  • Fairfield, Bush & Co sold 141 AbbVie shares in Q1 2026, an estimated $31.3K.
  • AbbVie made up 0.82% of Fairfield, Bush & Co's portfolio in Q1 2026, its #37 holding.
  • Fairfield, Bush & Co first reported a position in AbbVie in Q1 2018 and has held it in 24 quarters since.
  • Fairfield, Bush & Co's AbbVie position peaked at $1.58M in Q4 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fairfield, Bush & Co's 13F filing for Q1 2026, filed 12 May 2026.